Teza Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Teza Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,526	Closed	-$311K	–	653
2023 Q4	$311K	Buy	+2,526	New	+$315K	0.05%	405
2023 Q3	–	Sell	-5,347	Closed	-$663K	–	683
2023 Q2	$663K	Buy	5,347 +871	+19%	+$117K	0.11%	256
2023 Q1	$655K	Sell	4,476 -3,804	-46%	-$563K	0.14%	221
2022 Q4	$1.32M	Sell	8,280 -3,574	-30%	-$524K	0.25%	121
2022 Q3	$1.58M	Buy	+11,854	New	+$1.8M	0.33%	79
2021 Q1	–	Sell	-3,339	Closed	-$551K	–	513
2020 Q4	$551K	Buy	+3,339	New	+$497K	0.31%	109
2020 Q3	–	Sell	-1,991	Closed	-$220K	–	492
2020 Q2	$220K	Buy	+1,991	New	+$220K	0.05%	469
2020 Q1	–	Sell	-5,918	Closed	-$883K	–	316
2019 Q4	$883K	Buy	5,918 +2,591	+78%	+$353K	0.24%	119
2019 Q3	$426K	Buy	+3,327	New	+$446K	0.11%	299
2018 Q4	–	Sell	-1,472	Closed	-$247K	–	405
2018 Q3	$247K	Sell	1,472 -234	-14%	-$40.2K	0.06%	330
2018 Q2	$294K	Buy	+1,706	New	+$279K	0.04%	422

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Teza Capital Management's JAZZ Position: Q1 2024 in Review

Teza Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2024, closing a stake of 2,526 shares — an estimated $311K sold.

Teza Capital Management first reported a position in JAZZ in Q2 2018 and held it in 11 quarters. The position peaked at $1.58M in Q3 2022. 481 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.

Teza Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Teza Capital Management sold 2,526 Jazz Pharmaceuticals shares in Q1 2024, an estimated $311K.
Teza Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 11 quarters.
Teza Capital Management's Jazz Pharmaceuticals position peaked at $1.58M in Q3 2022.
481 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.

Based on Teza Capital Management's 13F filing for Q1 2024, filed 15 May 2024.